It may be due to the complex interplay of the tumor microenvironment, tracer pharmacokinetics, and heterogeneous tumor response to radiotherapy, in addition to a high level of caspase-3 that can efficiently process both cold and hot tracers. The gene discussed is CASP3; the disease is neoplasm.